Standard BioTools Inc. (NASDAQ:LAB) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 7.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,748 shares of the company’s stock after purchasing an additional 9,995 shares during the period. JPMorgan Chase & Co.’s holdings in Standard BioTools were worth $270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Wolverine Trading LLC purchased a new position in shares of Standard BioTools in the third quarter worth about $27,000. Xponance Inc. acquired a new position in Standard BioTools in the 2nd quarter worth approximately $34,000. Nisa Investment Advisors LLC lifted its stake in Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after acquiring an additional 14,732 shares during the period. Creative Planning purchased a new stake in shares of Standard BioTools in the 3rd quarter valued at $39,000. Finally, Algert Global LLC purchased a new stake in shares of Standard BioTools in the 2nd quarter valued at $44,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, TD Cowen decreased their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Stock Up 1.9 %

Standard BioTools stock opened at $1.61 on Friday. The business’s 50-day moving average price is $1.82 and its 200 day moving average price is $1.89. The firm has a market cap of $599.34 million, a price-to-earnings ratio of -2.27 and a beta of 1.57. Standard BioTools Inc. has a 52 week low of $1.21 and a 52 week high of $3.04.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.